CN110290803A - 膀胱癌的抗pd-l1抗体治疗 - Google Patents

膀胱癌的抗pd-l1抗体治疗 Download PDF

Info

Publication number
CN110290803A
CN110290803A CN201880011428.2A CN201880011428A CN110290803A CN 110290803 A CN110290803 A CN 110290803A CN 201880011428 A CN201880011428 A CN 201880011428A CN 110290803 A CN110290803 A CN 110290803A
Authority
CN
China
Prior art keywords
subject
antigen
bladder cancer
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880011428.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.库尔兰德
J.A.布莱克-哈斯金斯
M.扎加克
M.雷贝拉托
A.古普塔
T.何
J.沃克
X.金
S.莫里斯
R.杨诺内
L.施
M.达
Y.本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN202410133870.XA priority Critical patent/CN118001389A/zh
Publication of CN110290803A publication Critical patent/CN110290803A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880011428.2A 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗 Pending CN110290803A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410133870.XA CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
US62/459700 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410133870.XA Division CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Publications (1)

Publication Number Publication Date
CN110290803A true CN110290803A (zh) 2019-09-27

Family

ID=63169615

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410133870.XA Pending CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗
CN201880011428.2A Pending CN110290803A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410133870.XA Pending CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Country Status (12)

Country Link
US (2) US20190359715A1 (enExample)
EP (1) EP3582805A4 (enExample)
JP (2) JP2020507596A (enExample)
KR (3) KR20230145547A (enExample)
CN (2) CN118001389A (enExample)
AU (2) AU2018221822A1 (enExample)
CA (1) CA3052652A1 (enExample)
EA (1) EA201991870A1 (enExample)
IL (3) IL320916A (enExample)
MA (1) MA47509A (enExample)
SG (1) SG11201907211TA (enExample)
WO (1) WO2018152415A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023025321A2 (pt) * 2014-05-13 2024-02-20 Medimmune Limited Uso de anticorpos anti-b7-h1 e anti-ctla-4
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
WO2021234150A1 (en) * 2020-05-21 2021-11-25 Astrazeneca Ab Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150328331A1 (en) * 2003-05-23 2015-11-19 Nektar Therapeutics Compositions Comprising a Polymeric Reagent and a Pharmacologically Active Agent
WO2016196298A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023025321A2 (pt) * 2014-05-13 2024-02-20 Medimmune Limited Uso de anticorpos anti-b7-h1 e anti-ctla-4
BR112017018234A2 (pt) * 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
EP3448428A4 (en) * 2016-04-25 2019-11-27 Medimmune, LLC COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150328331A1 (en) * 2003-05-23 2015-11-19 Nektar Therapeutics Compositions Comprising a Polymeric Reagent and a Pharmacologically Active Agent
WO2016196298A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOAQUIN BELLMUNT等: "A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now" *

Also Published As

Publication number Publication date
IL268460A (en) 2019-09-26
IL320916A (en) 2025-07-01
EP3582805A1 (en) 2019-12-25
SG11201907211TA (en) 2019-09-27
US20220332828A1 (en) 2022-10-20
CA3052652A1 (en) 2018-08-23
JP2020507596A (ja) 2020-03-12
EP3582805A4 (en) 2021-03-10
EA201991870A1 (ru) 2020-02-12
KR20230145547A (ko) 2023-10-17
KR20190117014A (ko) 2019-10-15
IL302777A (en) 2023-07-01
US20190359715A1 (en) 2019-11-28
JP2024038034A (ja) 2024-03-19
AU2025201227A1 (en) 2025-03-13
MA47509A (fr) 2019-12-25
CN118001389A (zh) 2024-05-10
KR20250025517A (ko) 2025-02-21
WO2018152415A1 (en) 2018-08-23
AU2018221822A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
US20220332828A1 (en) Anti-pd-l1 antibody treatment of bladder cancer
US20160060344A1 (en) Combination therapy for pd-l1 negative tumors
EP4386005A2 (en) Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
JP2020512340A (ja) 無細胞ｄｎａによって測定される全身腫瘍組織量
CN112292151B (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
US20240376206A1 (en) Compositions and methods for treating late stage lung cancer
WO2021160152A1 (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
JP2022517087A (ja) 癌の治療のためのｔｉｍ－３抗体および他のチェックポイント阻害剤との組み合わせ
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
KR20250116698A (ko) Dll3-발현 암의 치료 방법
CN116209466A (zh) 抗pd-1抗体在治疗鼻咽癌中的用途
CN119630418A (zh) 抗GARP-TGF-β1/PD-1组合疗法
GB2535256A (en) Combination therapy for PD-L1 negative tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination